Novo Nordisk officially launched an oral formulation of its GLP‑1 obesity drug Wegovy in the U.S., listing insured patient copays as low as $25 per month and a cash price of $149 for starting doses. Clinical trial data cited by the company showed the highest 25‑mg oral dose produced average weight loss of about 16.6% at 64 weeks, comparable to injectable regimens at approved doses. The pill roll‑out aims to lower access barriers for patients and expand the market for incretin‑based obesity treatments while raising questions about demand management, coverage, and cost to payers. The launch intensifies competition in the obesity sector and shifts attention to prescribing patterns, reimbursement, and long‑term safety monitoring.